Fast multimode MRI based emergency assessment of hyperacute stroke thrombolysis.
OBJECTIVE
To investigate the value of fast multimode magnetic resonance imaging (MRI) based emergency assessment hyperacute stroke thrombolysis.


METHODS
One hundred and twenty four patients with 12 hour window acute ischemic strokes were examined by fast multimode MRI, and among them, 46 patients with hyperacute cerebral infarction confirmed by fast multimode MRI were treated by recombinant tissue plasminogen activator and followed up periodically by MRI.


RESULTS
The 46 patients selected by fast multimode MRI to receive thrombolytics demonstrated clinical improvement with 90 days modified Rankin scale scores < or =2 and life quality Barthal index of 80-100. Six patients developed asymptomatic intracranial hemorrhage (13.0%) 1-7 days after receiving thrombolytics.


CONCLUSIONS
Patients suffering from hyperacute ischemic cerebral infarction that are strong candidates for intravenous thrombolytic therapy can be identified by multimode MRI, especially for those whose time windows were undefined or beyond 3 hours after symptom onset. Fast multimodal MRI based selection of the hyperacute stroke model is more feasible compared with the traditional diffusion weighted imaging/perfusion weighted imaging mismatch model for the emergency assessment of hyperacute stroke thrombolysis.
Zhao
Zhenguo
Z
Department of Radiology, People's Hospital of Pudong New Area, Shanghai, China. zhaozhenguo1@sina.com
Bai
Qingke
Q
Sui
Haijing
H
Xie
Xiuhai
X
Wen
Feng
F
D000328:Adult; D000368:Aged; D020520:Brain Infarction / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods; D004632:Emergency Medical Services; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed / Q000379:methods
D010959:Tissue Plasminogen Activator